Real-World Safety and Efficacy of Transcatheter Mitral Valve Repair With MitraClip: Thirty-Day Results From the Italian Society of Interventional Cardiology (GIse) Registry Of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO)

Bedogni, Francesco; Testa, Luca; Rubbio, Antonio Popolo; Bianchi, G.; Grasso, Carmelo; Scandura, Salvatore; Marco, Federico De; Tusa, Maurizio; Denti, Paolo; Alfieri, Ottavio; Giordano, Arturo; Ferraro, Paolo; Bartorelli, Antonio L.; Mongiardo, Annalisa; Petronio, Anna Sonia; Giannini, Cristina; Felice, Francesco De; Baldi, Cesare; Castriota, Fausto; Adamo, Marianna; Masiero, Giulia; Godino, Cosmo; Montorfano, Matteo; Tarantini, Giuseppe; Tamburino, Corrado

doi:10.1016/j.carrev.2020.01.002

Cited by 26 publications

(24 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The GIOTTO registry is a multicenter, prospective registry including patients with symptomatic MR who underwent TEER with the MitraClip system (Abbott Vascular, Santa Clara, California) in 19 Italian centers. Patients were enrolled between January 2016 and March 2020 with ongoing follow‐up 17,18 . We excluded from the present analysis patients with primary MR and those with unsuccessful MitraClip, defined as the presence of MR > 2+ after the procedure.…”

Section: Methodsmentioning

confidence: 99%

Predictors of optimal procedural result after transcatheter edge‐to‐edge mitral valve repair in secondary mitral regurgitation

Adamo

Pagnesi

Rubbio

et al. 2022

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Predictors of optimal procedural result after transcatheter edge‐to‐edge mitral valve repair in secondary mitral regurgitation

Adamo

Pagnesi

Rubbio

et al. 2022

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

show abstract

“…The GIOTTO registry is an ongoing single‐arm, multicentre, prospective registry of patients with symptomatic MR who underwent TMVr with the MitraClip in Italy. Qualifying inclusion and exclusion criteria, echocardiographic selection and protocols employed, as well as details of the MitraClip procedure have been reported previously 13 …”

Section: Methodsmentioning

confidence: 99%

Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and residual mitral regurgitation after MitraClip implantation

Bedogni

Rubbio

Grasso

et al. 2021

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

Aims The Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO) was conceived in order to assess the safety and efficacy of MitraClip therapy in Italy. The aim of this study was to assess procedural and mid‐term outcomes, and clinical and echocardiographic predictors of mid‐term mortality after MitraClip therapy, stratifying the results according to the diagnosis of functional and degenerative mitral regurgitation (FMR vs. DMR). Methods and results Between January 2016 and March 2020, 1659 patients were prospectively included in the GIOTTO registry (FMR 59.4% vs. DMR 40.6%). Acute Mitral Valve Academic Research Consortium (MVARC) technical success was achieved in 97.2% of patients, without differences between FMR and DMR and with sustained results at 30 days. In the study population, all‐cause mortality was 4.0%, 17.5% and 34.6% at 30 days, 1 year and 2 years, respectively. Cardiovascular death was the most frequent cause of mortality. Overall hospitalization rates were 6.3%, 23.4% and 31.7% at 30 days, 1 year and 2 years, respectively. The most frequent cause of hospitalization was heart failure, particularly in the first 30 days. FMR and MVARC structural and functional failure were strongly associated with 1‐year mortality. Residual mitral regurgitation 1+ (rMR) was independently related to a reduced risk of 1‐year mortality (hazard ratio 0.62; P = 0.005). Coherently, at 2‐year follow up, FMR was associated with worse outcomes than DMR, and Kaplan–Meier all‐cause mortality was related to rMR. Conclusions Functional mitral regurgitation aetiology affects 1‐year mortality after MitraClip implantation, and differences in mortality and hospitalization rates between FMR and DMR can be observed within 2 years. Optimal rMR 1+ was correlated to a more favourable mid‐term outcome, particularly in FMR.

show abstract

“…They reported by means of a meta-regression analysis that larger left ventricular end-diastolic volume index (LVEDVi) is closely related to a higher risk of all-cause mortality, CV mortality and cardiac-related hospitalization after PMVR. Similarly, the GIOTTO registry showed favorable acute and 30-day safety and efficacy 9 . Interestingly, we expanded these findings identifying a cut-off of 92 ml/m 2 of LVEDVi, which has proven to be independently correlated with CV death or rehospitalization for HF.…”

Section: Discussionmentioning

confidence: 89%

“…Possible reasons for this sharp discordance include more selective patient recruitment in the COAPT trial compared to MITRA-FR trial, more severe MR and less dilated ventricles (LVEDVi 101 ml/m 2 vs 135 ml/m 2 , respectively). However, large registries 9 , 10 on MitraClip therapy demonstrated the continuous need for outcome data derived from industry-independent multicenter studies. In this study, a single-centre retrospective registry, we sought to evaluate the clinical outcomes and to identify predictors of rehospitalization for heart failure or cardiovascular death from a registry of patients with MR undergoing PMVR with the MitraClip system.…”

Section: Introductionmentioning

confidence: 99%

Predictors of outcomes in patients with mitral regurgitation undergoing percutaneous valve repair

Polimeni

Albanese

Salerno

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

Percutaneous mitral valve repair has been increasingly performed worldwide after approval. We sought to investigate predictors of clinical outcome in patients with mitral regurgitation undergoing percutaneous valve repair. The MITRA-UMG study, a single-centre registry, retrospectively collected consecutive patients with symptomatic moderate-to-severe or severe MR undergoing MitraClip therapy. The primary endpoint was the composite of cardiovascular death or rehospitalization for heart failure. Between March 2012 and July 2018, a total of 150 consecutive patients admitted to our institution were included. Procedural success was obtained in 95.3% of patients. The composite primary endpoint of cardiovascular death or rehospitalization for HF was met in 55 patients (37.9%) with cumulative incidences of 7.6%, 26.2%, at 30 days and 1-year, respectively. In the Cox multivariate model, NYHA functional class and left ventricular end-diastolic volume index (LVEDVi), independently increased the risk of the primary endpoint at long-term follow-up. At Kaplan–Meier analysis, a LVEDVi > 92 ml/m2 was associated with an increased incidence of the primary endpoint. In this study, patients presenting with dilated ventricles (LVEDVi > 92 ml/m2) and advanced heart failure symptoms (NYHA IV) at baseline carried the worst prognosis after percutaneous mitral valve repair.

show abstract

Real-World Safety and Efficacy of Transcatheter Mitral Valve Repair With MitraClip: Thirty-Day Results From the Italian Society of Interventional Cardiology (GIse) Registry Of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO)

Cited by 26 publications

References 30 publications

Predictors of optimal procedural result after transcatheter edge‐to‐edge mitral valve repair in secondary mitral regurgitation

Predictors of optimal procedural result after transcatheter edge‐to‐edge mitral valve repair in secondary mitral regurgitation

Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and residual mitral regurgitation after MitraClip implantation

Predictors of outcomes in patients with mitral regurgitation undergoing percutaneous valve repair

Contact Info

Product

Resources

About